Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy

Introduction: Primary membranous nephropathy (PMN) is most often caused by autoantibodies to phospholipase A2 receptor (PLA2R). M-PLACE (NCT04145440) is an open-label, phase 1b/2a study that assessed the safety and efficacy of the fully human anti-CD38 monoclonal antibody felzartamab in high-risk an...

Full description

Saved in:
Bibliographic Details
Main Authors: Brad H. Rovin, Pierre M. Ronco, Jack F.M. Wetzels, Sharon G. Adler, Isabelle Ayoub, Philippe Zaoui, Seung Hyeok Han, Jaideep S. Dudani, Houston N. Gilbert, Uptal D. Patel, Paul T. Manser, Julia Jauch-Lembach, Nicola Faulhaber, Rainer Boxhammer, Stefan Härtle, Ben Sprangers
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:Kidney International Reports
Subjects:
clinical trial
felzartamab
MOR202
phase 2
phospholipase A2 receptor
primary membranous nephropathy
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924017947
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468024924017947

Similar Items